Positive two-year Ph III VISTA trial of Eylea in DME

10 February 2014

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) and partner Germany’s Bayer (BAYN: DE) have released positive results from the Phase III VISTA-DME trial of Eylea (aflibercept) injection for the treatment of diabetic macular edema (DME).

Eylea, which was approved in the USA for the treatment of neovascular (wet) age-related macular degeneration (AMD) in November 2011 and for macular edema following central retinal vein occlusion (CRVO) in September 2012, generated sales of $1.01 billion for Regeneron in the first nine months of 2103 and the company projected that, for the full year, revenues would come in at between $1.35 billion and $1.375 billion (The Pharma Letter November 6, 2013). Bayer has rights to the product outside the USA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK